Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Gains from Sales and Divestitures (2020 - 2025)

Rein Therapeutics filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $1.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $1.0 million, changed N/A over the prior year.
  • Gains from Sales and Divestitures hit $1.0 million in Q4 2025 for Rein Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.0 million in Q3 2025, with the low at $12500.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 3 years was $250000.0 (2021), compared with a mean of $407812.5.
  • The sharpest move saw Gains from Sales and Divestitures surged 525.0% in 2021, then changed 0.0% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $250000.0 in 2021, then tumbled by 95.0% to $12500.0 in 2022, then skyrocketed by 7900.0% to $1.0 million in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.0 million, $1.0 million, and $12500.0 for Q4 2025, Q3 2025, and Q4 2022 respectively.